Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Plans for phase 2 trial of anticancer agent in elderly poor-risk AML patients announced
February 27th, 2006
Vion Pharmaceuticals, Inc. (VION) announced that it plans to conduct a pivotal phase 2 trial of its anticancer agent Cloretazine in elderly patients with poor-risk acute myelogenous leukemia (AML). This new trial, Vion CLI-043, will focus on elderly patients with de novo poor-risk AML. The company met recently with the U.S. Food and Drug Administration (FDA) to discuss data from Vion CLI-033, a phase 2 trial in patients with AML and high-risk myelodysplastic syndromes (MDS). In Stratum A of that trial, patients over the age of 60 with previously untreated AML and high-risk MDS are treated with Cloretazine as a single agent. In this stratum, a response rate (CR plus CRp)...
Source: Pharma Business Week (2006-02-27)
|
